tetano
Editor, Senior Moderator
Viruses
. 2022 Feb 10;14(2):370.
doi: 10.3390/v14020370.
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
Susan L Uprichard[SUP] 1 2 3 [/SUP], Amornrat O'Brien[SUP] 2 [/SUP], Monika Evdokimova[SUP] 2 [/SUP], Cynthia L Rowe[SUP] 2 [/SUP], Cara Joyce[SUP] 4 [/SUP], Matthew Hackbart[SUP] 2 [/SUP], Yazmin E Cruz-Pulido[SUP] 2 [/SUP], Courtney A Cohen[SUP] 5 6 [/SUP], Michelle L Rock[SUP] 5 6 [/SUP], John M Dye[SUP] 5 [/SUP], Paul Kuehnert[SUP] 7 [/SUP], Keersten M Ricks[SUP] 7 [/SUP], Marybeth Casper[SUP] 1 [/SUP], Lori Linhart[SUP] 1 [/SUP], Katrina Anderson[SUP] 1 [/SUP], Laura Kirk[SUP] 1 [/SUP], Jack A Maggiore[SUP] 8 [/SUP], Andrew S Herbert[SUP] 5 [/SUP], Nina M Clark[SUP] 1 3 [/SUP], Gail E Reid[SUP] 1 3 [/SUP], Susan C Baker[SUP] 2 3 [/SUP]
Affiliations
Abstract
Understanding the magnitude of responses to vaccination during the ongoing SARS-CoV-2 pandemic is essential for ultimate mitigation of the disease. Here, we describe a cohort of 102 subjects (70 COVID-19-naïve, 32 COVID-19-experienced) who received two doses of one of the mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)). We document that a single exposure to antigen via infection or vaccination induces a variable antibody response which is affected by age, gender, race, and co-morbidities. In response to a second antigen dose, both COVID-19-naïve and experienced subjects exhibited elevated levels of anti-spike and SARS-CoV-2 neutralizing activity; however, COVID-19-experienced individuals achieved higher antibody levels and neutralization activity as a group. The COVID-19-experienced subjects exhibited no significant increase in antibody or neutralization titer in response to the second vaccine dose (i.e., third antigen exposure). Finally, we found that COVID-19-naïve individuals who received the Moderna vaccine exhibited a more robust boost response to the second vaccine dose (p = 0.004) as compared to the response to Pfizer-BioNTech. Ongoing studies with this cohort will continue to contribute to our understanding of the range and durability of responses to SARS-CoV-2 mRNA vaccines.
Keywords: BNT162B2; COVID-19; SARS-CoV-2; antibodies; mRNA-1273; vaccine response.
. 2022 Feb 10;14(2):370.
doi: 10.3390/v14020370.
Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naïve and Experienced Individuals
Susan L Uprichard[SUP] 1 2 3 [/SUP], Amornrat O'Brien[SUP] 2 [/SUP], Monika Evdokimova[SUP] 2 [/SUP], Cynthia L Rowe[SUP] 2 [/SUP], Cara Joyce[SUP] 4 [/SUP], Matthew Hackbart[SUP] 2 [/SUP], Yazmin E Cruz-Pulido[SUP] 2 [/SUP], Courtney A Cohen[SUP] 5 6 [/SUP], Michelle L Rock[SUP] 5 6 [/SUP], John M Dye[SUP] 5 [/SUP], Paul Kuehnert[SUP] 7 [/SUP], Keersten M Ricks[SUP] 7 [/SUP], Marybeth Casper[SUP] 1 [/SUP], Lori Linhart[SUP] 1 [/SUP], Katrina Anderson[SUP] 1 [/SUP], Laura Kirk[SUP] 1 [/SUP], Jack A Maggiore[SUP] 8 [/SUP], Andrew S Herbert[SUP] 5 [/SUP], Nina M Clark[SUP] 1 3 [/SUP], Gail E Reid[SUP] 1 3 [/SUP], Susan C Baker[SUP] 2 3 [/SUP]
Affiliations
- PMID: 35215962
- DOI: 10.3390/v14020370
Abstract
Understanding the magnitude of responses to vaccination during the ongoing SARS-CoV-2 pandemic is essential for ultimate mitigation of the disease. Here, we describe a cohort of 102 subjects (70 COVID-19-naïve, 32 COVID-19-experienced) who received two doses of one of the mRNA vaccines (BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna)). We document that a single exposure to antigen via infection or vaccination induces a variable antibody response which is affected by age, gender, race, and co-morbidities. In response to a second antigen dose, both COVID-19-naïve and experienced subjects exhibited elevated levels of anti-spike and SARS-CoV-2 neutralizing activity; however, COVID-19-experienced individuals achieved higher antibody levels and neutralization activity as a group. The COVID-19-experienced subjects exhibited no significant increase in antibody or neutralization titer in response to the second vaccine dose (i.e., third antigen exposure). Finally, we found that COVID-19-naïve individuals who received the Moderna vaccine exhibited a more robust boost response to the second vaccine dose (p = 0.004) as compared to the response to Pfizer-BioNTech. Ongoing studies with this cohort will continue to contribute to our understanding of the range and durability of responses to SARS-CoV-2 mRNA vaccines.
Keywords: BNT162B2; COVID-19; SARS-CoV-2; antibodies; mRNA-1273; vaccine response.